Robin Jones to Patient Selection
This is a "connection" page, showing publications Robin Jones has written about Patient Selection.
Connection Strength
0.030
-
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016 Jul 30; 388(10043):488-97.
Score: 0.030